Cargando…
04. ASSESSMENT OF EFFICACY AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH INTRACRANIAL METASTATIC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
INTRODUCTION: Intracranial metastatic disease (IMD) is a serious and life-altering complication for many patients with cancer. Targeted therapy may address limitations of current treatments as an additional agent to achieve intracranial disease control in some patients with IMD. Osimertinib is a mut...
Autores principales: | Erickson, Anders, Brastianos, Priscilla, Das, Sunit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401362/ http://dx.doi.org/10.1093/noajnl/vdaa073.000 |
Ejemplares similares
-
Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis
por: Erickson, Anders W., et al.
Publicado: (2020) -
SYST-03 INCIDENCE AND SURVIVAL OF PATIENTS WITH INTRACRANIAL METASTATIC DISEASE AND ERBB2-POSITIVE GASTROINTESTINAL CANCERS: A RETROSPECTIVE COHORT STUDY
por: Sherman, Madison, et al.
Publicado: (2022) -
THER-01. Targeted therapy and intracranial metastatic disease: a population-based retrospective cohort study
por: Erickson, Anders, et al.
Publicado: (2021) -
34. TARGETED THERAPY FOR HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Erickson, Anders, et al.
Publicado: (2020) -
The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival
por: Erickson, Anders W., et al.
Publicado: (2019)